In: Hofmann , M A , Giménez-Arnau , A , Aberer , W , Bindslev-Jensen , C & Zuberbier , T 2018 , ' MI (2-methyl-4-isothiazolin-3-one) contained in detergents is not detectable in machine washed textiles ' , Clinical and Translational Allergy , vol. 8 , 1 . https://doi.org/10.1186/s13601-017-0187-2
Background: European legislation has banned the preservative methylisothiazolinone (MI) from inclusion in leave-on cosmetics. However, the risk for allergic reactions depends on exposure. The aim of this study was to determine the risk of MI in laundry detergents for household machine washing. Methods: Different formulations of laundry detergents with commercial MI levels, up to one thousand ppm were used and three different types of clothes were washed in a normal household machine setting one time and 10 times. The level of MI was measured by HPLC. Results: While MI could be retrieved in the positive control of clothes drenched with washing powder but not washed afterwards, MI could not be detected in any specimen of clothes washed under household conditions. The detection limit was 0.5 ppm. Conclusion: It is important to discuss the difference of risk and hazard. While MI clearly is a high hazard as a strong contact allergen, the risk depends on exposure. Regarding the risk of exposure levels for the consumer to MI in clothes it can be stated that the use of MI in laundry detergents is safe for the consumer if these products are used according to the instructions in the normal household setting machine wash.
Altres ajuts: Funding - The study was supported by the European Centre for Allergy Research Foundation. ; European legislation has banned the preservative methylisothiazolinone (MI) from inclusion in leave-on cosmetics. However, the risk for allergic reactions depends on exposure. The aim of this study was to determine the risk of MI in laundry detergents for household machine washing. Different formulations of laundry detergents with commercial MI levels, up to one thousand ppm were used and three different types of clothes were washed in a normal household machine setting one time and 10 times. The level of MI was measured by HPLC. While MI could be retrieved in the positive control of clothes drenched with washing powder but not washed afterwards, MI could not be detected in any specimen of clothes washed under household conditions. The detection limit was 0.5 ppm. It is important to discuss the difference of risk and hazard. While MI clearly is a high hazard as a strong contact allergen, the risk depends on exposure. Regarding the risk of exposure levels for the consumer to MI in clothes it can be stated that the use of MI in laundry detergents is safe for the consumer if these products are used according to the instructions in the normal household setting machine wash.
In: Dhami , S , Nurmatov , U , Pajno , G B , Fernandez-Rivas , M , Muraro , A , Roberts , G , Akdis , C , Alvaro-Lozano , M , Beyer , K , Bindslev-Jensen , C , Burks , W , du Toit , G , Ebisawa , M , Eigenmann , P , Knol , E , Makela , M , Nadeau , K C , O'Mahony , L , Papadopoulos , N , Poulsen , L , Sackesen , C , Sampson , H , Santos , A , van Ree , R , Timmermans , F & Sheikh , A 2017 , ' Erratum to : Allergen immunotherapy for IgE-mediated food allergy: Protocol for a systematic review (Clinical and Translational Allergy (2016) 6 (24) DOI:10.1186/s13601-016-0113-z) ' , Clinical and Translational Allergy , vol. 7 , 31 . https://doi.org/10.1186/s13601-017-0166-7
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is notacknowledged. This section should be corrected to the below: Funding EAACI and the BM4SIT project (Grant Number 601763) in the European Union's Seventh Framework ProgrammeFP7.
BACKGROUND: Asthma, rhinitis and eczema often co-occur in children, but their interrelationships at the population level have been poorly addressed. We assessed co-occurrence of childhood asthma, rhinitis and eczema using unsupervised statistical techniques. METHODS: We included 17 209 children at 4 years and 14 585 at 8 years from seven European population-based birth cohorts (MeDALL project). At each age period, children were grouped, using partitioning cluster analysis, according to the distribution of 23 variables covering symptoms 'ever' and 'in the last 12 months', doctor diagnosis, age of onset and treatments of asthma, rhinitis and eczema; immunoglobulin E sensitization; weight; and height. We tested the sensitivity of our estimates to subject and variable selections, and to different statistical approaches, including latent class analysis and self-organizing maps. RESULTS: Two groups were identified as the optimal way to cluster the data at both age periods and in all sensitivity analyses. The first (reference) group at 4 and 8 years (including 70% and 79% of children, respectively) was characterized by a low prevalence of symptoms and sensitization, whereas the second (symptomatic) group exhibited more frequent symptoms and sensitization. Ninety-nine percentage of children with comorbidities (co-occurrence of asthma, rhinitis and/or eczema) were included in the symptomatic group at both ages. The children's characteristics in both groups were consistent in all sensitivity analyses.CONCLUSION:At 4 and 8 years, at the population level, asthma, rhinitis and eczema can be classified together as an allergic comorbidity cluster. Future research including time-repeated assessments and biological data will help understanding the interrelationships between these diseases. ; This work was supported by Mechanisms of the Develop-ment of ALLergy (MeDALL), a collaborative project con-ducted within the European Union under the HealthCooperation Work Programme of the 7th Framework pro-gramme (grant agreement No. 261357)
International audience ; The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Sante good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation.
International audience ; The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Sante good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation.
International audience ; The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Sante good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation.
In: Zuberbier , T , Abdul Latiff , A H , Abuzakouk , M , Aquilina , S , Asero , R , Baker , D , Ballmer-Weber , B , Bangert , C , Ben-Shoshan , M , Bernstein , J A , Bindslev-Jensen , C , Brockow , K , Brzoza , Z , Chong Neto , H J , Church , M K , Criado , P R , Danilycheva , I V , Dressler , C , Ensina , L F , Fonacier , L , Gaskins , M , Gáspár , K , Gelincik , A , Giménez-Arnau , A , Godse , K , Gonçalo , M , Grattan , C , Grosber , M , Hamelmann , E , Hébert , J , Hide , M , Kaplan , A , Kapp , A , Kessel , A , Kocatürk , E , Kulthanan , K , Larenas-Linnemann , D , Lauerma , A , Leslie , T A , Magerl , M , Makris , M , Meshkova , R Y , Metz , M , Micallef , D , Mortz , C G , Nast , A , Oude-Elberink , H , Pawankar , R , Pigatto , P D , Ratti Sisa , H , Rojo Gutiérrez , M I , Saini , S S , Schmid-Grendelmeier , P , Sekerel , B E , Siebenhaar , F , Siiskonen , H , Soria , A , Staubach-Renz , P , Stingeni , L , Sussman , G , Szegedi , A , Thomsen , S F , Vadasz , Z , Vestergaard , C , Wedi , B , Zhao , Z & Maurer , M 2022 , ' The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria ' , Allergy: European Journal of Allergy and Clinical Immunology , vol. 77 , no. 3 , pp. 734-766 . https://doi.org/10.1111/all.15090
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
In: Zuberbier , T , Abdul Latiff , A H , Abuzakouk , M , Aquilina , S , Asero , R , Baker , D , Ballmer-Weber , B , Bangert , C , Ben-Shoshan , M , Bernstein , J A , Bindslev-Jensen , C , Brockow , K , Brzoza , Z , Chong Neto , H J , Church , M K , Criado , P R , Danilycheva , I V , Dressler , C , Ensina , L F , Fonacier , L , Gaskins , M , Gáspár , K , Gelincik , A , Giménez-Arnau , A , Godse , K , Gonçalo , M , Grattan , C , Grosber , M , Hamelmann , E , Hébert , J , Hide , M , Kaplan , A , Kapp , A , Kessel , A , Kocatürk , E , Kulthanan , K , Larenas-Linnemann , D , Lauerma , A , Leslie , T A , Magerl , M , Makris , M , Meshkova , R Y , Metz , M , Micallef , D , Mortz , C G , Nast , A , Oude-Elberink , H , Pawankar , R , Pigatto , P D , Ratti Sisa , H , Rojo Gutiérrez , M I , Saini , S S , Schmid-Grendelmeier , P , Sekerel , B E , Siebenhaar , F , Siiskonen , H , Soria , A , Staubach-Renz , P , Stingeni , L , Sussman , G , Szegedi , A , Thomsen , S F , Vadasz , Z , Vestergaard , C , Wedi , B , Zhao , Z & Maurer , M 2022 , ' The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria ' , Allergy: European Journal of Allergy and Clinical Immunology . https://doi.org/10.1111/all.15090 ; ISSN:0105-4538
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
In: Bousquet , J J , Schünemann , H J , Togias , A , Erhola , M , Hellings , P W , Zuberbier , T , Agache , I , Ansotegui , I J , Anto , J M , Bachert , C , Becker , S , Bedolla-Barajas , M , Bewick , M , Bosnic-Anticevich , S , Bosse , I , Boulet , L P , Bourrez , J M , Brusselle , G , Chavannes , N , Costa , E , Cruz , A A , Czarlewski , W , Fokkens , W J , Fonseca , J A , Gaga , M , Haahtela , T , Illario , M , Klimek , L , Kuna , P , Kvedariene , V , Le , L T T , Larenas-Linnemann , D , Laune , D , Lourenço , O M , Menditto , E , Mullol , J , Okamoto , Y , Papadopoulos , N , Pham-Thi , N , Picard , R , Pinnock , H , Roche , N , Roller-Wirnsberger , R E , Rolland , C , Samolinski , B , Sheikh , A , Toppila-Salmi , S , Tsiligianni , I , Bindslev-Jensen , C , Eller , E , Ulrik , C S & ARIA Study Group 2019 , ' Next-generation ARIA care pathways for rhinitis and asthma : a model for multimorbid chronic diseases ' , Clinical and Translational Allergy , vol. 9 , 44 . https://doi.org/10.1186/s13601-019-0279-2
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
In: Zuberbier , T , Abdul Latiff , A H , Abuzakouk , M , Aquilina , S , Asero , R , Baker , D , Ballmer-Weber , B , Bangert , C , Ben-Shoshan , M , Bernstein , J A , Bindslev-Jensen , C , Brockow , K , Brzoza , Z , Chong Neto , H J , Church , M K , Criado , P R , Danilycheva , I V , Dressler , C , Ensina , L F , Fonacier , L , Gaskins , M , Gáspár , K , Gelincik , A , Giménez-Arnau , A , Godse , K , Gonçalo , M , Grattan , C , Grosber , M , Hamelmann , E , Hébert , J , Hide , M , Kaplan , A , Kapp , A , Kessel , A , Kocatürk , E , Kulthanan , K , Larenas-Linnemann , D , Lauerma , A , Leslie , T A , Magerl , M , Makris , M , Meshkova , R Y , Metz , M , Micallef , D , Mortz , C G , Nast , A , Oude-Elberink , H , Pawankar , R , Pigatto , P D , Ratti Sisa , H , Rojo Gutiérrez , M I , Saini , S S , Schmid-Grendelmeier , P , Sekerel , B E , Siebenhaar , F , Siiskonen , H , Soria , A , Staubach-Renz , P , Stingeni , L , Sussman , G , Szegedi , A , Thomsen , S F , Vadasz , Z , Vestergaard , C , Wedi , B , Zhao , Z & Maurer , M 2022 , ' The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria ' , Allergy: European Journal of Allergy and Clinical Immunology , vol. 77 , no. 3 , pp. 734-766 . https://doi.org/10.1111/all.15090
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.
International audience ; The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Sante good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation.
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Nextgeneration guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement. ; info:eu-repo/semantics/publishedVersion
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.